Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Ostrava
About this trial
The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.
Eligibility criteria
Qualifiers
ECMO support with anticoagulation using argatroban/enoxaparin
Age ≥ 18 years
Obtaining informed consent in accordance with the procedure specified in the protocol
Disqualifiers
Enrolment in the lung transplant program at Motol University Hospital
Known hypersensitivity to the components of the evaluated products
Allergic reaction to the active ingredients of the evaluated products
Pregnancy and breastfeeding
Trial design
Treatments tested in this trial
- Low anticoagulation dose of argatroban and enoxaparin during ECMO
- Standard anticoagulation dose of argatroban and enoxaparin during ECMO
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Hospital Ostrava
Lead sponsor
University Hospital, Motol
Collaborator
Source ClinicalTrials.gov